BioSpace News Archive

Brooklyn ImmunoTherapeutics, Inc. announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering by certain selling stockholders of up to 6,281,454 shares of Brooklyn’s common stock received in connection with Brooklyn’s acquisition of Novellus, Inc. in July 2021.

BioNTech SE today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for BNT111, an investigational cancer immunotherapy for the potential treatment of advanced melanoma.

Evofem Biosciences, Inc., today announced that Chief Executive Officer Saundra Pelletier will participate in a fireside chat and host one-on-one meetings at the Piper Sandler 33rd Annual Virtual Healthcare Conference being held from November 29 – December 2, 2021.

Chimerix today announced the presentation of positive data from its 50-patient efficacy analysis of ONC201 with a Conference Call at 8:30 a.m. ET on Monday, November 22.

Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Cato T. Laurencin, M.D., Ph.D., to the company’s Board of Directors.

Glaukos Corporation announced that its management is scheduled to virtually participate in the following upcoming investor conferences

Castle Biosciences, Inc. today announced the publication of a study of patients with stage I-III cutaneous melanoma.

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the New Drug Application (NDA) for mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to April 28, 2022.

Voyager Therapeutics, Inc. today will present preclinical data demonstrating that IV dosing of a proprietary AAV vector identified by the TRACER™️ screening technology, encoding an anti-HER2 antibody payload, prevented tumor growth in models of HER2+ brain metastases.

BridgeBio Pharma, Inc. announced they have entered into a strategic collaboration to co-develop and co-commercialize a potentially first-in-class inhibitor designed to target glutathione peroxidase 4 (GPX4) with the hope of providing an effective new therapy for patients with difficult-to-treat tumors.